Somatic Mutation Profiling and Associations with Prognosis and Trastuzumab Benefit in Early Breast Cancer

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2013 Jun 7

PMID 23739063

Citations 72

Authors

Sherene Loi

Stefan Michiels

Diether Lambrechts

Debora Fumagalli

Bart Claes

Pirkko-Liisa Kellokumpu-Lehtinen

Petri Bono

Vesa Kataja

Martine J Piccart

Heikki Joensuu

Christos Sotiriou

Affiliations

Soon will be listed here.

Abstract

Background: Certain somatic alterations in breast cancer can define prognosis and response to therapy. This study investigated the frequencies, prognostic effects, and predictive effects of known cancer somatic mutations using a randomized, adjuvant, phase III clinical trial dataset.

Methods: The FinHER trial was a phase III, randomized adjuvant breast cancer trial involving 1010 women. Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer were further randomized to 9 weeks of trastuzumab or no trastuzumab. Seven hundred five of 1010 tumors had sufficient DNA for genotyping of 70 somatic hotspot mutations in 20 genes using mass spectrometry. Distant disease-free survival (DDFS), overall survival (OS), and interactions with trastuzumab were explored with Kaplan-Meier and Cox regression analyses. All statistical tests were two-sided.

Results: Median follow-up was 62 months. Of 705 tumors, 687 were successfully genotyped. PIK3CA mutations (exons 1, 2, 4, 9, 13, 18, and 20) were present in 25.3% (174 of 687) and TP53 mutations in 10.2% (70 of 687). Few other mutations were found: three ERBB2 and single cases of KRAS, ALK, STK11/LKB1, and AKT2. PIK3CA mutations were associated with estrogen receptor positivity (P < .001) and the luminal-A phenotype (P = .04) but were not statistically significantly associated with prognosis (DDFS: hazard ratio [HR] = 0.88, 95% confidence [CI] = 0.58 to 1.34, P = .56; OS: HR = 0.603, 95% CI = .32 to 1.13, P = .11), although a statistically significant nonproportional prognostic effect was observed for DDFS (P = .002). PIK3CA mutations were not statistically significantly associated with trastuzumab benefit (P(interaction): DDFS P = .14; OS P = .24).

Conclusions: In this dataset, targeted genotyping revealed only two alterations at a frequency greater than 10%, with other mutations observed infrequently. PIK3CA mutations were associated with a better outcome, however this effect disappeared after 3 years. There were no statistically significant associations with trastuzumab benefit.

Citing Articles

Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.

Afolabi H, Salleh S, Zakaria Z, Seng C, Nafi S, Aziz A Discov Oncol. 2025; 16(1):268.

PMID: 40048017 PMC: 11885200. DOI: 10.1007/s12672-025-01960-2.

HER2-Positive Breast Cancer Treatment and Resistance.

Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M Adv Exp Med Biol. 2025; 1464():495-525.

PMID: 39821040 DOI: 10.1007/978-3-031-70875-6_24.

Breast cancer genomic analyses reveal genes, mutations, and signaling networks.

Manjunath G, Sharma S, Nashier D, Vasanthaiah S, Jha S, Bage S Funct Integr Genomics. 2024; 24(6):206.

PMID: 39496981 DOI: 10.1007/s10142-024-01484-y.

PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.

Ren X, Cui H, Dai L, Chang L, Liu D, Yan W J Cancer Res Clin Oncol. 2024; 150(3):119.

PMID: 38466449 PMC: 10927816. DOI: 10.1007/s00432-024-05626-4.

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.

Zagami P, Fernandez-Martinez A, Rashid N, Hoadley K, Spears P, Curigliano G JAMA Netw Open. 2023; 6(12):e2348814.

PMID: 38117494 PMC: 10733807. DOI: 10.1001/jamanetworkopen.2023.48814.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Frasor J, Danes J, Komm B, Chang K, Lyttle C, Katzenellenbogen B . Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003; 144(10):4562-74. DOI: 10.1210/en.2003-0567. View

Ellis M, Lin L, Crowder R, Tao Y, Hoog J, Snider J . Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2009; 119(2):379-90. PMC: 2810126. DOI: 10.1007/s10549-009-0575-y. View

Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S . SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol. 2010; 25(1):72-82. PMC: 3089033. DOI: 10.1210/me.2010-0294. View

Park S, Jiang Z, Mortenson E, Deng L, Radkevich-Brown O, Yang X . The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010; 18(2):160-70. PMC: 2923645. DOI: 10.1016/j.ccr.2010.06.014. View

Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M . NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008; 68(19):8022-30. DOI: 10.1158/0008-5472.CAN-08-1385. View

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379(9816):633-40. PMC: 5705192. DOI: 10.1016/S0140-6736(11)61847-3. View

10.

Perez-Tenorio G, Alkhori L, Olsson B, Waltersson M, Nordenskjold B, Rutqvist L . PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007; 13(12):3577-84. DOI: 10.1158/1078-0432.CCR-06-1609. View

11.

Lee J, Soung Y, Seo S, Kim S, Park C, Wang Y . Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 2006; 12(1):57-61. DOI: 10.1158/1078-0432.CCR-05-0976. View

12.

Yarden R, Wilson M, Chrysogelos S . Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl. 2001; Suppl 36:232-46. DOI: 10.1002/jcb.1142. View

13.

Kancha R, von Bubnoff N, Bartosch N, Peschel C, Engh R, Duyster J . Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One. 2011; 6(10):e26760. PMC: 3203921. DOI: 10.1371/journal.pone.0026760. View

14.

Weigelt B, Warne P, Downward J . PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene. 2011; 30(29):3222-33. DOI: 10.1038/onc.2011.42. View

15.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

16.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

17.

Vasudevan K, Barbie D, Davies M, Rabinovsky R, McNear C, Kim J . AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009; 16(1):21-32. PMC: 2752826. DOI: 10.1016/j.ccr.2009.04.012. View

18.

Kalinsky K, Jacks L, Heguy A, Patil S, Drobnjak M, Bhanot U . PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009; 15(16):5049-59. DOI: 10.1158/1078-0432.CCR-09-0632. View

19.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K . PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008; 68(19):8127-36. DOI: 10.1158/0008-5472.CAN-08-0755. View

20.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View